NCT05138692

Brief Summary

After written consent from next-of-kin patients with severe traumatic brain injury was included from the neurointensive care unit (NICU) at Sahlgrenska university hospital, Gothenburg. Blood and CSF samples were collected during the initial 3 weeks after trauma. 1 year after trauma patients were assessed according to Glasgow outcome scale (GOS), NIHSS and Barthels. 10-15 years after trauma a repeated evaluation according to GOS was performed by telephone. Different biomarkers such as Neurofilament light, Glial fibrillary acidic protein and Tau among others, was analyzed from serum and CSF samples. Further patients were explored Apolipoprotein-E genetype (APOE). The investigators hypothesize that higher biomarkers concentrations and positive test for this gene relate to worse outcome 1-year and 10-15 years after trauma. Further that these biomarkers and genetic marker further have prognostic value on outcome 1-year and 10-15 years after trauma. Finally, the investigators want to explore the concentrations dynamics of these biomarkers in serum and CSF in the acute phase after trauma.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
99

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2000

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2000

Completed
16.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
5 years until next milestone

First Submitted

Initial submission to the registry

November 18, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 1, 2021

Completed
Last Updated

December 1, 2021

Status Verified

November 1, 2021

Enrollment Period

16.2 years

First QC Date

November 18, 2021

Last Update Submit

November 30, 2021

Conditions

Outcome Measures

Primary Outcomes (4)

  • In severe traumatic brain injury patient; Correlation of Neurochemical biomarkers analyzed in CSF and serum, assessed in the initial ICU period, correlated to Glasgow Outcome Scale (GOS) at 1 year post-trauma

    GOS 1-3 - Poor outcome, GOS 4-5 Good outcome

    1 year after trauma

  • In severe traumatic brain injury patient; Correlation of Neurochemical biomarkers analyzed in CSF and serum, assessed in the initial ICU period, correlated to Glasgow Outcome Scale (GOS) at 10-15 years post-trauma

    GOS 1-3 - Poor outcome, GOS 4-5 Good outcome

    10-15 years after trauma

  • In severe traumatic brain injury patient; correlation of the genetic alleles of APOE correlated to Glasgow Outcome Scale (GOS) at 1-year post-trauma)

    GOS 1-3 - Poor outcome, GOS 4-5 Good outcome

    1 year after trauma

  • In severe traumatic brain injury patient; correlation of the genetic alleles of APOE correlated to Glasgow Outcome Scale (GOS) at 10-15 years post-trauma)

    GOS 1-3 - Poor outcome, GOS 4-5 Good outcome

    10-15 years after trauma

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patient with severe traumatic brain injury, defined by our inclusion criteria, where enrolled from the Neurointensive care unit at Sahlgrenska university hospital, Gothenburg. Sahlgrenska University hospital is a tertiary hospital admitting patients from the whole south west part of Sweden.

You may qualify if:

  • Reaction level scale \>3, corresponding to a Glasgow coma scale \<9
  • A therapeutic indication for intracranial pressure monitoring
  • Need for ventilator treatment

You may not qualify if:

  • Not residing in Sweden

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sahlgrenska University Hospital

Mölndal, Västra Götaland County, 431 80, Sweden

Location

Biospecimen

Retention: SAMPLES WITH DNA

Biomarkers Neurofilament light (NFL) and Glial Fibrillary Acid Protein (GFAP) were analyzed in CSF, TAU in serum, APOE- genotype was explored in whole blood

MeSH Terms

Conditions

Disease

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Bengt Nellgård, MD PhD Professor

    University of Gothenburg and Västra götaland Regionen, Sahlgrenska Universitetssjukhus Mölndal

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
15 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

November 18, 2021

First Posted

December 1, 2021

Study Start

October 1, 2000

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

December 1, 2021

Record last verified: 2021-11

Locations